Researchers at the University of Cambridge have generated fully characterised, conditional knock-in mouse models for essential thrombocythemia (ET) and related myelofibrosis (PMF) that are available to license for preclinical studies. This mouse line conditionally expresses a mutant Calreticulin with humanized novel C terminus which is found in human patients, under the control of the endogenous mouse locus.
Essential thrombocythemia (ET) and Primary myelofibrosis (MF) are two types of myeloid proliferative neoplasms (MPNs). MPNs are chronic hematologic malignancies that arise in the hematopoietic stem cell compartment and share a variable propensity to transform to acute myeloid leukaemia.
In ET and PMF, 50-60% of patients carry a JAK2 mutation. Of the non-JAK2 mutated patients, 70-80% carry mutations in calreticulin (CALR) which encodes an endoplasmic reticulum chaperone.
Heterozygous CALRdel/+ mice present with:
Homozygous CALRdel/+ mice present with:
Both the ET and MF murine models have been robustly characterised, and are valuable preclinical models available for non-exclusive licensing.
Tony Green
Professor of Haemato-Oncology; Director of the Wellcome – MRC Cambridge Stem Cell Institute
Tony has held multiple academic, clinical and educational leadership roles, both nationally and internationally, has been appointed to visiting professorships at several universities, was elected Fellow of the Academy of Medical Sciences (2001) and President of the European Haematology Association (2015-2017). Recent awards include the Jean Bernard Award by the European Haematology Association (2020) and the Donald Metcalf award by the International Society for Experimental Hematology (2021).
Mutant calreticulin knock-in mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage, Green et al., Blood, 2018, doi: 10.1182/blood-2017-09-806356.
Banner image: Essential Thrombocythemia, Peripheral Blood, from Ed Uthman via Flickr, Attribution (CC BY 2.0)
To find out more about how this website collects your personal data see www.enterprise.cam.ac.uk/about-us/information-compliance/data-protection/core-privacy-notices/website-users-use-personal-information/